Polar Asset Management Partners’s Regeneron Pharmaceuticals REGN Stock Holding History

Polar Asset Management Partners’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-400	Closed	-$420K	–	772
2024 Q3	$420K	Sell	400 -900	-69%	-$1M	0.01%	468
2024 Q2	$1.37M	Sell	1,300 -3,720	-74%	-$3.61M	0.03%	365
2024 Q1	$4.83M	Sell	5,020 -4,480	-47%	-$4.26M	0.08%	215
2023 Q4	$8.34M	Sell	9,500 -16,400	-63%	-$13.5M	0.14%	138
2023 Q3	$21.3M	Buy	25,900 +12,500	+93%	+$9.82M	0.47%	52
2023 Q2	$9.63M	Buy	+13,400	New	+$10.3M	0.17%	158
2020 Q3	–	Sell	-1,280	Closed	-$798K	–	690
2020 Q2	$798K	Buy	+1,280	New	+$727K	0.01%	328

Other funds holding REGN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Polar Asset Management Partners's REGN Position: Q4 2024 in Review

Polar Asset Management Partners sold out of Regeneron Pharmaceuticals (REGN) in Q4 2024, closing a stake of 400 shares — an estimated $420K sold.

Polar Asset Management Partners first reported a position in REGN in Q2 2020 and held it in 7 quarters. The position peaked at $21.3M in Q3 2023. 1,320 funds tracked by Wall St. Rank hold REGN as of Q4 2024.

Polar Asset Management Partners reported no remaining Regeneron Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
Polar Asset Management Partners sold 400 Regeneron Pharmaceuticals shares in Q4 2024, an estimated $420K.
Polar Asset Management Partners first reported a position in Regeneron Pharmaceuticals in Q2 2020 and held it in 7 quarters.
Polar Asset Management Partners's Regeneron Pharmaceuticals position peaked at $21.3M in Q3 2023.
1,320 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q4 2024.

Based on Polar Asset Management Partners's 13F filing for Q4 2024, filed 14 Feb 2025.